Cargando…

Lymphocyte Activation Gene 3 (Lag3) Contributes to α-Synucleinopathy in α-Synuclein Transgenic Mice

Aggregation of misfolded α-synuclein (α-syn) is the major component of Lewy bodies and neurites in Parkinson’s disease (PD) and related α-synucleinopathies. Some α-syn mutations (e.g., A53T) in familial PD recapitulate the α-syn pathology in transgenic mice, which supports the importance of patholog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Hao, Yang, Xiuli, Mao, Xiaobo, Xu, Enquan, Qi, Chen, Wang, Haibo, Brahmachari, Saurav, York, Bethany, Sriparna, Manjari, Li, Amanda, Chang, Michael, Patel, Pavan, Dawson, Valina L., Dawson, Ted M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987675/ https://www.ncbi.nlm.nih.gov/pubmed/33776654 http://dx.doi.org/10.3389/fncel.2021.656426

Ejemplares similares

The Interplay between α-Synuclein and Microglia in α-Synucleinopathies
por: Deyell, Jacob S., et al.
Publicado: (2023)

STING mediates neurodegeneration and neuroinflammation in nigrostriatal α-synucleinopathy
por: Hinkle, Jared T., et al.
Publicado: (2022)

Resistance to MPTP-Neurotoxicity in α-Synuclein Knockout Mice Is Complemented by Human α-Synuclein and Associated with Increased β-Synuclein and Akt Activation
por: Thomas, Bobby, et al.
Publicado: (2011)

Correction: Resistance to MPTP-Neurotoxicity in α-Synuclein Knockout Mice Is Complemented by Human α-Synuclein and Associated with Increased β-Synuclein and Akt Activation
por: Thomas, Bobby, et al.
Publicado: (2012)

Determinants of seeding and spreading of α-synuclein pathology in the brain
por: Henrich, Martin T., et al.
Publicado: (2020)

Cerebral Microvascular Injury Induced by Lag3‐Dependent α‐Synuclein Fibril Endocytosis Exacerbates Cognitive Impairment in a Mouse Model of α‐Synucleinopathies
por: Zhang, Qingxi, et al.
Publicado: (2023)

LAG3 is not expressed in human and murine neurons and does not modulate α‐synucleinopathies
por: Emmenegger, Marc, et al.
Publicado: (2021)

Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies
por: Outeiro, Tiago Fleming, et al.
Publicado: (2008)

α-Synuclein interacts directly but reversibly with psychosine: implications for α-synucleinopathies
por: Abdelkarim, Hazem, et al.
Publicado: (2018)

Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies
por: Kawahata, Ichiro, et al.
Publicado: (2022)

α-Synuclein conformers reveal link to clinical heterogeneity of α-synucleinopathies
por: Schmitz, Matthias, et al.
Publicado: (2023)

Propagative α-synuclein seeds as serum biomarkers for synucleinopathies
por: Okuzumi, Ayami, et al.
Publicado: (2023)

α-Synuclein oligomers and fibrils: partners in crime in synucleinopathies
por: Bigi, Alessandra, et al.
Publicado: (2023)

Cellular Milieu Imparts Distinct Pathological α-Synuclein Strains in α-Synucleinopathies
por: Peng, Chao, et al.
Publicado: (2018)

Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy
por: Wennström, Malin, et al.
Publicado: (2013)

α-Synuclein Transgenic Drosophila As a Model of Parkinson's Disease and Related Synucleinopathies
por: Mizuno, Hideya, et al.
Publicado: (2010)

Triggering of Inflammasome by Aggregated α–Synuclein, an Inflammatory Response in Synucleinopathies
por: Codolo, Gaia, et al.
Publicado: (2013)

Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson’s disease
por: Jakova, Elisabet, et al.
Publicado: (2022)

Possible Alterations in β-Synuclein, the Non-Amyloidogenic Homologue of α-Synuclein, during Progression of Sporadic α-Synucleinopathies
por: Fujita, Masayo, et al.
Publicado: (2012)

Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy
por: Spencer, Brian, et al.
Publicado: (2017)

Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid
por: Na, Chan Hyun, et al.
Publicado: (2020)

α-Synuclein pathology in post-mortem retina and optic nerve is specific for α-synucleinopathies
por: Hart de Ruyter, Frederique J., et al.
Publicado: (2023)

Modulation of α-synuclein expression in transgenic animals for modelling synucleinopathies — is the juice worth the squeeze?
por: Buchman, Vladimir L., et al.
Publicado: (2008)

Fyn kinase regulates misfolded α-synuclein uptake and NLRP3 inflammasome activation in microglia
por: Panicker, Nikhil, et al.
Publicado: (2019)

Tau Enhances α-Synuclein Aggregation and Toxicity in Cellular Models of Synucleinopathy
por: Badiola, Nahuai, et al.
Publicado: (2011)

Lovastatin Alleviates α-Synuclein Aggregation and Phosphorylation in Cellular Models of Synucleinopathy
por: Dai, Lijun, et al.
Publicado: (2021)

α-Synuclein Strains: Does Amyloid Conformation Explain the Heterogeneity of Synucleinopathies?
por: Hoppe, Simon Oliver, et al.
Publicado: (2021)

Lipotoxicity Downstream of α-Synuclein Imbalance: A Relevant Pathomechanism in Synucleinopathies?
por: Tripathi, Arati, et al.
Publicado: (2021)

Gut Microbiome-Modified Polyphenolic Compounds Inhibit α-Synuclein Seeding and Spreading in α-Synucleinopathies
por: Yamasaki, Tritia R., et al.
Publicado: (2020)

Modeling α-Synucleinopathy in Organotypic Brain Slice Culture with Preformed α-Synuclein Amyloid Fibrils
por: Roux, Amandine, et al.
Publicado: (2020)

Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy
por: Kallab, Martin, et al.
Publicado: (2018)

The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease
por: Karuppagounder, Senthilkumar S., et al.
Publicado: (2014)

Role of α- and β-Synucleins in the Axonal Pathology of Parkinson’s Disease and Related Synucleinopathies
por: Sekigawa, Akio, et al.
Publicado: (2015)

Skin α-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study
por: Donadio, V., et al.
Publicado: (2018)

In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons
por: Fouka, Maria, et al.
Publicado: (2020)

A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies
por: Hartlage-Rübsamen, Maike, et al.
Publicado: (2021)

Conditional transgenic mice expressing C-terminally truncated human α-synuclein (αSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons
por: Daher, João Paulo L, et al.
Publicado: (2009)

Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice
por: Luk, Kelvin C., et al.
Publicado: (2012)

Increased Neuronal α-Synuclein Pathology Associates with Its Accumulation in Oligodendrocytes in Mice Modeling α-Synucleinopathies
por: Kisos, Haya, et al.
Publicado: (2012)

Autonomic ganglionic injection of α-synuclein fibrils as a model of pure autonomic failure α-synucleinopathy
por: Wang, Xue-Jing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nflcg4d72cpu8c5f1m933fku5u